Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. [electronic resource]
Producer: 20090219Description: 491-7 p. digitalISSN:- 1527-7755
- Adult
- Aged
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Agents -- administration & dosage
- Antineoplastic Agents, Alkylating -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Cyclophosphamide -- administration & dosage
- Drug Administration Schedule
- Female
- Flow Cytometry
- Follow-Up Studies
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Male
- Middle Aged
- Polymerase Chain Reaction
- Remission Induction
- Rituximab
- Vidarabine -- administration & dosage
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.